Scholarlink

<p>The renin-angiotensin system plays a key role in bone metabolism. While the classical renin-angiotensin system axis promotes bone resorption, the counter-regulatory axis, including alamandine via MrgprD receptor, favors bone formation. This study evaluated the therapeutic effects of alamandine in a model of osteoporosis. <i>In vitro</i>, alamandine reduced osteoclast activation and size in a MrgprD receptor-dependent manner. <i>In vivo</i>, ovariectomy-induced osteoporosis reduced bone parameters, and alamandine reversed trabecular bone loss in wild-type mice but not in MrgprD knockout mice, demonstrating the essential role of the receptor. Alamandine also reduced serum calcium and phosphorus levels in ovariectomized wild-type mice, with no effect on ovariectomized knockout animals. Furthermore, modulation of iron levels differed between genotypes, suggesting the involvement of ferroptosis-related pathways. Histological analysis revealed an increase in the number of osteoblasts and osteocytes in wild-type mice treated with alamandine, corroborating its role in osteogenic differentiation, possibly via the AMPK/eNOS pathway. In contrast, alamandine exacerbated bone resorption in ovariectomized MrgprD knockout mice, potentially through alternative renin-angiotensin system receptors. In conclusion, alamandine increases bone formation and reduces resorption through MrgprD receptor signaling, highlighting its potential as a therapeutic agent in osteoporosis.</p> Graphical Abstract

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Alamandine/MrgprD as a Key Player in Antiresorptive Effects in an Osteoporosis Experimental Model

  • 期刊论文

  • 发表日期：

    2026年3月9日

查看全文
  • Letícia Cristina Dias Lima,
  • Isabella Ramos Cavalcante,
  • Felipe Emanuel Oliveira Rocha,
  • Jader Oliva Jorge,
  • Talita Martins,
  • Mila Fernandes Moreira Madeira,
  • Maria José Campagnole-Santos,
  • Soraia Macari,
  • Clésia Cristina Nascentes,
  • Eduardo Henrique Martins Nunes,
  • Celso Martins Queiroz-Junior,
  • Robson Augusto Souza dos Santos,
  • Paula Rocha Moreira,
  • Marcos Augusto de Sá

摘要

The renin-angiotensin system plays a key role in bone metabolism. While the classical renin-angiotensin system axis promotes bone resorption, the counter-regulatory axis, including alamandine via MrgprD receptor, favors bone formation. This study evaluated the therapeutic effects of alamandine in a model of osteoporosis. In vitro, alamandine reduced osteoclast activation and size in a MrgprD receptor-dependent manner. In vivo, ovariectomy-induced osteoporosis reduced bone parameters, and alamandine reversed trabecular bone loss in wild-type mice but not in MrgprD knockout mice, demonstrating the essential role of the receptor. Alamandine also reduced serum calcium and phosphorus levels in ovariectomized wild-type mice, with no effect on ovariectomized knockout animals. Furthermore, modulation of iron levels differed between genotypes, suggesting the involvement of ferroptosis-related pathways. Histological analysis revealed an increase in the number of osteoblasts and osteocytes in wild-type mice treated with alamandine, corroborating its role in osteogenic differentiation, possibly via the AMPK/eNOS pathway. In contrast, alamandine exacerbated bone resorption in ovariectomized MrgprD knockout mice, potentially through alternative renin-angiotensin system receptors. In conclusion, alamandine increases bone formation and reduces resorption through MrgprD receptor signaling, highlighting its potential as a therapeutic agent in osteoporosis.

Graphical Abstract